Sign up
Pharma Capital

Arix Bioscience’s investee company Aura Biosciences announces positive data from mid-stage eye cancer trial

The data from a phase Ib/II trial of Aura’s AU-011 eye cancer treatment show the injection doesn’t do too much damage to the surrounding healthy tissue in patients’ eyes
Ocular melanoma is the most common type of eye cancer

Arix Bioscience Plc’s (LON:ARIX) investee company Aura Biosciences has reported positive results from the phase Ib/II clinical trial of its AU-011 eye cancer injection.

AU-011 is made up of viral nanoparticles which latch onto and, once activated by an ophthalmic laser, kill cancer cells in the back of the eye.

READ: Arix boosted by LogicBio's Nasdaq IPO

Importantly, they do this without damaging the surrounding tissue, preserving patients’ vision.

Brian Marr, the trial’s principal investigator, said: “These 12-month data demonstrate that light-activated AU-011 continues to be well-tolerated, including with multiple administrations, has evidence of tumour control and preservation of visual acuity”

Arix chief investment officer Joe Anderson added: “We believe that this minimally invasive, non-radiation-based treatment option, has the potential to offer a new treatment option for patients.”

“We continue to support Aura as the company progresses towards a pivotal phase III study.”

Arix, which has a 6.6% stake in Aura, saw its shares drop 4.1% to 162.6p in late-afternoon trading.

View full ARIX profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.